As of 10/1/25, ALUNBRIG® (brigatinib) is covered at Cigna Healthcare*+.
This means that most commercial patients will have more rapid access to ALUNBRIG and a lower co-pay.
With this formulary update, ~99% of commercial lives are now covered for ALUNBRIG1.
Takeda hopes that this formulary update helps improve patient access and time to treatment start for ALUNBRIG.
For patients with commercial insurance who are concerned about out-of-pocket costs, the Takeda Oncology Co-Pay Assistance Program may be able to help reduce the out-of-pocket costs associated with ALUNBRIG. Terms and Conditions Apply. Visit us athttps://www.takedaoncologycopay.com/ to learn more.
Please note, ALUNBRIG’s limited distribution network remains unchanged. ALUNBRIG can be ordered from Biologics and Onco360 specialty pharmacies or purchased from the following specialty distributors to be dispensed through accounts that have a medically integrated pharmacy: ASD Healthcare, Cardinal Health Specialty Distribution, McKesson Plasma & Biologics, McKesson Specialty Care Distribution, and Oncology Supply.
*Subject to Prior Authorization and Quantity Limit. Benefits may vary by individual plans. Coverage is not guaranteed.
+ Status is representative of the coverage for the majority of members covered under each plan. This information is not intended to give advice or promise coverage or payment.
Reference: 1. Data on file. Takeda Pharmaceuticals U.S.A., Inc.; 2025.
To learn more about ALUNBRIG, please visit alunbrig.com.
